Trimetazidine-Teva is an antihypoxic drug stimulating the metabolism of the myocardium and sensorineural organs in case of ischemia. There is also another brand-name version of the drug called Vastarel.
Its active ingredient is trimetazidine which was the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). Trimetazidine is usually prescribed as a long-term treatment of angina pectoris, and in some countries (including France) for tinnitus and dizziness. Controlled studies in angina patients have shown that trimetazidine increases coronary flow reserve, thereby delaying the onset of ischemia associated with exercise, limits rapid swings in blood pressure without any significant variations in heart rate, significantly decreases the frequency of angina attacks, and leads to a significant decrease in the use of nitrates.
It improves left ventricular function in diabetic patients with coronary heart disease. Recently, it has been shown to be effective in patients with heart failure of different etiologies.
Trimetazidine inhibits beta-oxidation of fatty acids by blocking long-chain 3-ketoacyl-CoA thiolase, which enhances glucose oxidation. By preserving energy metabolism in cells exposed to hypoxia or ischemia, trimetazidine prevents a decrease in intracellular ATP levels, thereby ensuring the proper functioning of ionic pumps and transmembrane sodium-potassium flow whilst maintaining cellular homeostasis.
Buy Trimetazidine to stimulate the metabolism of cardiomyocytes and brain neuronal cells, thereby stabilizing oxygen consumption and myocardial contractility. In patients with angina pectoris, the drug has a pronounced effect of reducing blood pressure and regulating the heart rate after several weeks of administration.
Coronary heart disease with angina pectoris manifestations. The drug provides symptomatic treatment and prevents vascular vertigo, tinnitus, hearing impairment, and chorioretinal vascular disorders. Trimetazidine-Teva can be administered both individually and in combination with other antianginals in case if they do not provide the required effect.
During Olympics 2022, Kamila Valieva, a figure skater of the Russian Olympic Committee, has tested positive for trimetazidine. The substance is banned by the World Anti-Doping Association (WADA).
Produced by Teva, Israel.
Check out more Adaptogens at our store!
Coated tablets. In 1 tablet:
Active ingredients: trimetazidine dihydrochloride 20 mg and macrogol;
Inactive ingredients: microcrystalline cellulose, mannitol, magnesium stearate, titanium dioxide, and dyes.
Dosage and administration
To be administered orally. Dosage is 40–60 mg per day divided into 2-3 intakes. The length of the treatment course is to be prescribed by a doctor.
Pregnancy, lactation, and hypersensitivity to the components of the drug.
Allergic response (including skin allergies), vertigo, or headache.
No significant drug interactions were registered.
Store at a temperature not higher than 25°C (77°F). Keep out of the reach of children.
Shelf life is 2 years.
- K McClellan, G Plosker (1999) Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions https://www.ncbi.nlm.nih.gov/pubmed/10439934
- R Belardinelli (2000) Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy https://www.ncbi.nlm.nih.gov/pubmed/11206102
- H Cross (2001) Trimetazidine for stable angina pectoris https://www.ncbi.nlm.nih.gov/pubmed/11336628
- Chrusciel et al (2014) Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease
- C Dézsi (2016) Trimetazidine in Practice: Review of the Clinical and Experimental Evidence https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856171/
- Ciapponi et al (2017) Trimetazidine for stable angina https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464521/
- von Bredow et al (2018) Evaluation of the effectiveness of risk minimization measures for trimetazidine: A cross sectional joint PASS survey among physicians in selected European countries https://www.ncbi.nlm.nih.gov/pubmed/30379361/
- M Glezer (2018) The Effectiveness of Trimetazidine Treatment in Patients with Stable Angina Pectoris of Various Durations: Results from the CHOICE-2 Study https://www.ncbi.nlm.nih.gov/pubmed/29766461
$30.00 – $140.00
Derinat® is a native DNA-containing physiologically active drug with immunomodulating and immunostimulating properties. The active substance of Derinat – sodium deoxyribonucleate – is a biologically active substance that is obtained from specific cells of fish of the sturgeon class. Derinat has a high reparative and regenerative ability, anti-inflammatory and detoxifying effects, as well as antioxidant and membrane-stabilizing properties. This allows the use of the drug in complex and monotherapy.
$0.00 – $35.00
Cytamins® are proteins, nucleoproteins and minerals isolated from animal tissues using a patented technology. The main mechanism of the biological action of Cytamins is the correction of cellular metabolism in damaged cells of the tissue from which they are isolated. These peptide bioregulators are supplements that are safely used for anti-ageing purposes and as an aid to conventional treatment methods.
$7.00 – $9.00
Aminalon® is a substance with nootropic and psychostimulatory qualities. The active component of Aminalon is Gamma-Aminobutyric acid (GABA). The main property of GABA is that it regulates blood flow in the brain, improves memory, speech, and coordination. Patients suffering from diabetes also notice lowered blood sugar after Aminalon administration.
$10.00 – $46.00
Adaptol® (Mebicar) belongs to a group of non-benzodizepam tranquilizers. It is approved for use by the general public as an anxiolytic and a “daily” tranquilizer, because it does not disturb mental and motor performance. It is also used to aid smoking cessation and to treat ADHD symptoms. Fast US domestic shipping is available.